The following is a summary of “Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients ...

cream, 1% as a treatment for atopic dermatitis (AD) in adults and children two years of age and older. The new target date is March 12, 2025, revised from the original target action date of ...